Report an error   


Submitted: 07 May 2013 Modified: 22 June 2017
HERDIN Record #: PCHRD13050714474243

Botulinum toxin therapy in established post-stroke upper limb spasticity .

Raymond L. Rosales,
Mary Milred Delgado-De Los Santo,
Arlene R. Ng,
Criscely L. Go,
Michelle Joya-Tanglao

See More

Amongst stroke patients, more than a third will develop spasticity, especially those that involve the paretic upper limbs. Despite establish intensive rehabilitaion programs in place, spasticity still affect a post-stroke patient's quality of life and create significant economic and caregiver burdens. The rationale for botulinum toxin type A (BoNT-A) use in spasticity is hinged on the toxin's ability to reduce muscle overactivity via a dual cholinergic blockede of extrafusal and intrafusal muscle. Efficacy and safety of BoNT-A in established post-stroke spasticity have been widely published, effectively establishing robustness of data and first line recommendation. Consensus guidelines and algorithms on the clinical use of BoNT-A for symptomatic upper limb spasticity are now also available. While BoNT-A has been universally shown to reduce muscle tone in spasticity, optimizing therapy requires judicious use of the toxin, while raising one's consciousness of adverse event, including muscle weakness, unwanted or desired in therapy. BoNT-A should not be administered alone in post-stroke spasticity, and its effects are best optimized in concert with a comprehensive neurorehabilitation program.

Publication Type
Journal
Publication Sub Type
Journal Article, Original
Title
The Philippine Journal of Neurology
Frequency
Semi-Annual
Publication Date
August 2012
Volume
16
Issue
1
Page(s)
31-36
1. Lance, J W. "Symposium Synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control." Miami FL: Year Book Medical Publishers , 485-500, 1980
2. Bohannon, R W, Smith, M B. "Inter-rater reliability of a Modified Ashworth Scale of muscle spasticity." Phys Ther 67(2): 206-7, 1987
3. Rosales, R L. "Dystonia, Spasticity and Botulinum Toxin Therapy: Rationale, Evidences and Clinical Context:. In: Rosales RL, editor. Dystonia - The Many Facets." Rijeka Croatia: InTech , 83-98, 2012
4. Rosales, R L, Kanovsky, P , Fernandez, H H. "What" Parkinsonism and Rel Discord 17, S3-10, 2011
5. Dong, M , Yeh, F , Tepp, W H, Dean, C , Johnson, E A, Janz, R , et, al . "SV2 is the protein re-ceptor for botulinum neurotoxin A." Sci Exp 312, 592-6, 2006
6. Rossetto, O , Morbiato, L , Caccin, P , Rigoni, M , Montecucco, C . "Presynaptic enzymatic neurotoxins." J Neurochem 97, 1534-45, 2006
7. de Paiva, A , Meunier, F A, Molgo, J , Aoki, K R, Dolly, J O. "Functional repair of motor end-plates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic ac-tivity between nerve sprouts and their parent terminals. Proceedings of the Na-tional Academy of Sciences" USA 96, 3200-5, 1999
8. Rosales, R L, Arimura, K , Takenaga, S , Osame, M . "Extrafusal and intrafusal muscle ef-fects in experimental botulinum toxin-A injection." Muscle Nerve 19, 488-96, 1996
9. Rosales, R L, Dressler, D . "On muscle spindles, dystonia and botulinum toxin." Eur J Neurol 17(suppl 1): 71-80, 2010
10. Watkins, C L, Leathley, M J, Gregson, J M, Moore, A P, Smith, T L, Sharma, A K. "Prevalence of spasticity post stroke." Clin Rehabil 16, 515-22, 2002
11. Leathlet, M J, Gregson, J M, Moore, A P, Smith, T L, Sharma, A K, Watkins, C L. "Predicting spasticity after stroke in those surviving to 12 months." Clin Rehabil 18, 438-43, 2008
12. Lundstrom, E , Terent, A , Bong, J . "Prevalence of disabling spasticity 1 year after first-ever stroke." Eur J Neurol 15, 533-39, 2008
13. Feys, H M, De Weerdt, W J, Selz, B E, Steck, GA C, Spichiger, R , Vereeck, L E, et, al . "Effect of a therapeutic intervention for the hemiplegic upper limb in the acute phase after stroke: A single blind, randomized, controlled multicenter trial." Stroke 29, 785-92, 1998
14. Rosales, R L, Chua-Yap, A S. "Evidence based systematic review on the efficacy and safety of BoNT-A in post-stroke spasticity." J Neural Transm 115(4): 617-23, 2008
15. Olvey, E L, Armstrong, E P, Grizzle, A J. "Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review." Clin Ther 32, 2282-2303, 2010
16. Bakheit, AM O, Zakine, B , Maisonobe, P , Aymard, C , Fhedoroff, K , Hefter, H , et, al . "The profile of patients and current practice of treatment of upper limb muscle spastici-ty with botulinum toxin type a: an international survey." Int J Rehabil Res 33(3): 199-204, 2010
17. McCrory, P , Turner-Stokes, L , Baguley, I J, De Graaff, S , Katrak, P , Sandanam, J , et, al . "Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes." J Rehabil Med 41, 536-44, 2009
18. Turner-Stokes, L . "Goal attainment scaling and its relationship with standardized outcome measures: a commentary." J Rehabil Med 43, 70-2, 2011
19. Pandyan, A D, Johnson, G R, Price, C I, Curless, R H, Barnes, M P, Rodgers, H . "A review of the properties and limitations of the Ashworth and Modified Ashworth Scales as measures of spasticity." Clin Rehabil 13, 373-83, 1999
20. Simpson, D M, Gracies, J M, Graham, H K, Miyasaki, j m, Naumann, N , Russman, B , et, al . "Botulinum neurotoxin for the treatment of spasticity (an evidence based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology." Neurology 70, 1691-8, 2008
21. Turner-Stokes, L , Ashford, S , Bhakta, B , Heward, K , et, al . "Spasticity in adults: man-agement using botulinum toxin: national guidelines." London: Royal College of Phy-sicians , 2009
22. Wissel, J , Ward, A B, Erztgaard, P , Bensmail, D , Hecht, M J, Lejeune, T M, et, al . "European consensus table on the use of botulinum toxin type A in adult spasticity." J Rehabil Med 4, 113-25, 2009
23. Elia, A E, Filippini, G , Calandrella, D , Albanese, A . "Botulinum neurotoxins for post-stroke spasticity in adults: A systematic review." Mov Disord 24, 801-12, 2009
24. Sheean, G , Lannin, N A, Turner-Stokes, L , Rawicki, B , Snow, B J. "Botulinum toxin as-sessment, intervention and after-care for upper limb hypertonicity in adults: inter-national consensus statement." Eur J Neurol 17(suppl 2): 74-93, 2010
25. Bakheit, AM O, Fedorova, N V, Skoromets, A A, Timerbaeva, S L, Bhakta, B B, Coxon, L . "The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles." J Neurol Neurosurg Psychiatry 75, 1558-61, 2004
26. Lagalla, G , Danni, M , Reiter, F , Ceravolo, M G, Provinciali, L . "Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb." Am J Phys Med Rehabil 79, 377-84, 2000
27. Sheean, G . "Botulinum toxin should be first-line treatment for poststroke spasticity." J Neurol Neurosurg Psychiatry 80, 35, 2009
28. Bhakta, B B, O, R J, Cozens, J A. "Associated reactions after stroke: a randomized controlled trial of the effect of botulinum toxin type A." J Rehabil Med 40(1): 36-41, 2008
29. Brashear, A , Gordon, M F, Elovic, E , Kassicieh, V D, Marciniak, C , Do, M , et, al . "Intramus-cular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke." N Eng J Med 347, 395-400, 2002
30. Shaw, L C, Price, C I, van Wijck, F M, Shackley, p , Steen, N , Barnes, M P, et, al . "Botulinum toxin for the upper limb after stroke (Bo TULS) trial: effect on impairment, activity limitation, and pain." Stroke 42, 1371-9, 2011
31. Kaji, R , Osako, Y , Suyama, K , Maeda, T , Uechi, Y , Iwasaki, M , et, al . "Botulinum toxin type A in post-stroke upper limb spasticity." Curr Med Res Opin 26, 1983-92, 2010
32. Kanovsky, P , Slawek, J , Denes, Z , Platz, T , Sassin, U , Comes, G , et, al . "Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity." Clin Neuro-pharmacoI 32, 259-65, 2009
33. Bhakta, B B, Cozens, J A, Chamberlain, M A, Bamford, J M. "Impact of botulinum toxin type a on disability and carer burden due to arm spasticity after stroke: a random-ised double blind placebo controlled trial." J Neurol Neurosurg Psychiatry 69, 217-21, 2000
34. Muller, F , Cugy, E , Ducerf, C , Delleci, C , Guehl, D , Joseph, P A, et, al . "Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study." Clin Rehabil 26(2): 174-9, 2012
35. Shaw, L , Rodgers, H , Price, C , van Wijck, F , Shackley, p , Steen, N , et, al . "BoTULS: a mul-ticentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A." Health Technol Assess 14(26): 1-113, 2010
36. Ozcakir, S , Sivrioglu, K . "Botulinum toxin in post-stroke spasticity." Clin Med Res 5(2): 132-8, 2007
37. Welmer, A K, Widen, H L, Sommerfeld, D K. "Location and severity of spasticity in the first 1-2 weeks and at 3 and 18 months after stroke." Eur J Neurol 17, 720-5, 2009
38. Ward, A B. "Spasticity treatment with botulinum toxins." J. Neural Transm 115(4): 607-16, 2008
39. Lukban, M , Rosales, R L, Dressler, D . "Effectiveness of Botulinum Toxin A for Upper and Lower Limb Spasticity in Children with Cerebral Palsy: A Summary of Evidence" Journal of Neural Transmission 116, 319-331, 2009
40. Sloop, R R, Escutin, R O, Matus, J A, Cole, B A, Peterson, G W. "Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botu-linum toxin type A." Neurology 46, 1382-86, 1995
41. Rosales, R L, Bigalke, H , Dressler, D . "Pharmacology of botulinum toxin: differences between type A preparations." Eur J Neurol 13, 2-10, 2006